Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 10, 2008Journal of Clinical InvestigationOpen Access

Muramyl dipeptide activation of nucleotide-binding oligomerization domain 2 protects mice from experimental colitis

View Full Paper
Ask AI
Bookmark
Share

Authors

TWTomohiro WatanabeKindai University Sakai HospitalNANaoki AsanoTohoku UniversityPMPeter J. MurrayRoyal College of Surgeons in Ireland

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Watanabe et al. (2008) studied this question.

synapsesocial.com/papers/6a19acf405af093a17f6683fhttps://doi.org/10.1172/jci33145
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Antibodies to interleukin 12 abrogate established experimental colitis in mice.1995 · 1,348 citations
  2. 2Nod2 Mutation in Crohn's Disease Potentiates NF-κB Activity and IL-1ß Processing2005 · 755 citations
  3. 3Nucleotide-Binding Oligomerization Domain-2 Modulates Specific TLR Pathways for the Induction of Cytokine Release2005 · 275 citations
  4. 4Role of Nod2 in the Response of Macrophages to Toll-Like Receptor Agonists2003 · 261 citations
  5. 5NOD2 regulation of Toll-like receptor responses and the pathogenesis of Crohn’s disease2005 · 71 citations